Home Authors Posts by Jay W. Belle Isle
Jay W. Belle Isle
You pay your premiums faithfully, are never late, and bought into the promises made by your home insurer that you would be protected in the event of an emergency. Along comes a hurricane of epic proportions – Harvey had 130mph sustained winds, an enormous storm surge, and dropped several feet of rain in a relatively short period – and you lose everything. “But,” you think, “at least I’m insured. Everything will be fine.” Sadly, that’s not proving to be the case for many people. Delayed insurance claims are the new storm slamming Texans.
Lex Machina’s Legal Analytics® platform now includes District Court Bankruptcy Appeals. Lex Machina, a LexisNexis company, unveiled the latest expansion of its award-winning platform earlier this week. That announcement, and an explanation of the benefits of this expansion, are reproduced below, courtesy of the company.
I was recently contacted by a fellow writer about a piece published on the potential Bayer-Monsanto merger. It’s such an excellent, and in-depth, look at the issue that I asked him if I could publish an excerpt here. He graciously agreed. This is a potential merger that has far-reaching and negative effects for us all. As the piece says, the Bayer-Monsanto merger is truly a marriage made in Hell.
We’re pleased to share the news that “Judge Lorna G. Schofield of the U.S. District Court for the Southern District of New York has appointed Robins Kaplan LLP® attorney Holly Dolejsi as co-lead counsel in multidistrict litigation (MDL) involving the diabetes...
Whether you’re soon to graduate law school and are looking for a place to start your career, or are simply looking for a change, one of the best things you can do for yourself is researching places you’d like to go. For some, it may be easy: moving closer to family or friends is a must. Others may simply want to go where the legal jobs are plentiful and the cost of living is affordable. Discovering your perfect place can take a lot of research. Fortunately, the good people at Abodo did that research for you.
Earlier this month, Dutch pharmaceutical company Novo Nordisk settled eight suits, brought by the Department of Justice, claiming that the company violated the Federal Food, Drug, and Cosmetic Act (FDCA) and the False Claims Act (FCA). The DOJ asserted that the company had misbranded its popular Type II diabetes drug, Victoza, by failing to comply with an “FDA-mandated Risk Evaluation and Mitigation Strategy (REMS).” The company agreed to the settlement of $58.65M. That amount includes disgorgement (repayment of illegally-earned profits) of $12.15M for the FDCA violations, which the DOJ claimed took place from 2010 to 2012, and a $46.5M payment for the FCA violations. The latter, according to the DOJ, took place from 2010 to 2014.
Bayer, the manufacturer of the controversial “permanent” birth control device Essure, announced on September 18 that it is discontinuing all sales and marketing efforts of the device in all European markets. Citing “commercial reasons,” the company continued to stand by the safety and efficacy of the device despite tens of thousands of reported injuries. The Essure device will remain on the market in the U.S. For now.
Ella Ebaugh, a resident of Pennsylvania, knows about pain. She was diagnosed with stress urinary incontinence (SUI) in 2005. In 2007, Mrs. Ebaugh did as many women: she trusted that pelvic mesh implants would fix the problem. Also like many women, Mrs. Ebaugh discovered that the mesh devices – these made by Johnson & Johnson’s Ethicon division – caused more problems than they solved. Problems that ultimately lead Mrs. Ebaugh to sue J&J. Earlier this month, a jury in Philadelphia awarded Mrs. Ebaugh $57.1M.
As Texas continues its recovery from Harvey and Florida is just beginning its recovery from Irma, it looks as though history may repeat itself in that it will be necessary to catalog vehicles damaged by these two immense storms. This is a vitally important project, as flood damaged vehicles may not be safe, even though they appear fine.
The House of Representatives Subcommittee on Health is reviewing proposed legislation that could change the face of patient safety efforts nationwide. If passed, the Medical Device Safety Act will allow patients injured by a Class III medical device to take legal action against the manufacturer at the state court level. This is prohibited under current preemption protections. The balance of this post is a press release from the Essure Problems Facebook group. The E-Sisters are planning a rally in support of the Medical Device Safety Act. Information on the Act, and the rally, follows.